Blood biomarkers of Alzheimer's disease and progression across different stages of cognitive decline in the community.

Valletta M, Vetrano DL, Gregorio C, Rizzuto D, Winblad B, Canevelli M, Andersson S, Dale M, Fredolini C, Laukka EJ, Fratiglioni L, Grande G

Nat Commun - (-) - [2025-11-23; online 2025-11-23]

Blood biomarkers of Alzheimer's disease (AD) are promising for dementia prediction, but their association with progression across intermediate stages of cognitive decline in the general population remains unclear. We followed 2148 dementia-free individuals from a Swedish population-based cohort for up to 16 years. Associations between baseline AD blood biomarkers and transitions between normal cognition, mild cognitive impairment (MCI), and dementia were examined. Lower amyloid-β42/40 ratio and higher phosphorylated-tau181 (p-tau181), p-tau217, total-tau, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were associated with faster progression from MCI to all-cause and AD dementia, with the strongest associations for NfL and p-tau217. Elevated NfL and GFAP were linked to reduced MCI reversion to normal cognition, whereas no biomarker was associated with MCI development from normal cognition. These findings show robust group-level associations and indicate that AD blood biomarkers may help stratify dementia risk at the MCI stage in the community.

Affinity Proteomics Stockholm [Collaborative]

PubMed 41276530

DOI 10.1038/s41467-025-66728-2

Crossref 10.1038/s41467-025-66728-2

pii: 10.1038/s41467-025-66728-2